Biswas, S., & Bagchi, A
Patients reported, in interview forms, using the following drugs: brinzolamide, latanoprost, ripasudil, travoprost, carteolol, isopropyl unoprostone, tafluprost, timolol, bunazosin, bimatoprost, brimonidine, bromfenac, gatifloxacin, levofloxacin, phenylephrine and tropicamide
E., & Rossignol, D
A 2025 narrative review published in PubMed Central identified serious safety risks associated with IV glutathione administration specifically, anaphylaxis, hepatotoxicity, and the lack of standardized dosing protocols and concluded that IV glutathione must be restricted to closely monitored clinical settings under physician oversight
Benfotiamine enhances antioxidant defenses and protects against cisplatin-induced DNA damage in nephrotoxic rats